Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis

Needham besides accrued its terms people for Centessa to $38 from $35 with a Buy standing connected the shares connected January 5. The steadfast anticipated that the company’s momentum would persist into 2026, driven by upcoming information from Phase 2a dose-escalation cohorts for ORX-750. Furthermore, Needham identified Centessa arsenic 1 of the astir compelling acquisition targets successful the biotech assemblage for the coming year.

Earlier connected December 10, Oppenheimer resumed sum of Centessa with an Outperform standing and an accrued terms people of $62, up from $40. Labeling the institution a apical pick, the steadfast highlighted Centessa’s best-in-class orexin agonists and a projected commercialized motorboat successful H1 2028. Oppenheimer viewed Centessa arsenic importantly undervalued and anticipated important maturation driven by objective information readouts scheduled for 2026 and beyond.

Centessa Pharmaceuticals (NASDAQ:CNTA) is simply a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines.

While we admit the imaginable of CNTA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.